Down syndrome, autism spectrum disorder, cancer, diabetes, cystic fibrosis, and sickle cell anemia are a few of the commonly known genetic disorders. Some genetic disorders cause symptoms at birth, while others develop over time. The global burden of genetic diseases appears to be increasing. According to the National Center for Biotechnology Information (NCBI), a US-based medical organization, as of November 2021, genetic disorders were identified in 9.4% of pediatric patients, with 44.7% being critically ill newborns. In addition, 13.17 million patients in the US suffer from unique genetic disorders. According to the Centers for Disease Control and Prevention (CDC) 2022 report, sickle cell disease affects ~100,000 Americans, and it occurs in 1 in 356 African American births. Cystic fibrosis, another common genetic disease worldwide, affects ~30,000 US citizens, and ~1,000 new cases are treated annually. Enzymatic DNA synthesis is a well-established DNA synthesis technique useful in synthetic biology, genetic engineering, and therapeutic antibody studies. In conjunction with enzymatic assays, DNA synthesis shows greater diagnostic possibilities. This method provides important information about people at risk and helps them make important decisions regarding disease diagnosis and medication. Hence, with the rising prevalence of genetic disorders across the world, people are becoming more aware of the need for the early detection of these genetic flaws, which propels the growth of the North America enzymatic DNA synthesis market.
The North America enzymatic DNA synthesis market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2021. The projected growth of the enzymatic DNA synthesis market in North America is attributed to the factors such as the presence of leading market players and their product developments and rising prevalence of genetic disorders.
The North America enzymatic DNA synthesis market is segmented on the basis of product type, application, technology, end user, and country.
Based on product type, the North America enzymatic DNA synthesis market is bifurcated into custom DNA synthesis and DNA library synthesis. The DNA library synthesis segment held a larger market share in 2022.
Based on application, the North America enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and others. The synthetic biology segment held the largest market share in 2022.
Based on technology, the North America enzymatic DNA synthesis market is segmented into SOLA, CRISPR, PCR, and others. The PCR segment held the largest market share in 2022.
Based on end user, the North America enzymatic DNA synthesis market is segmented into academic & research institutes, biotech & pharmaceutical companies, diagnostic laboratories, and others. The biotech and pharmaceutical companies segment held the largest market share in 2022
Based on country, the North America enzymatic DNA synthesis market is segmented into the US, Canada, and Mexico. The US dominated the North America enzymatic DNA synthesis market share in 2022.
Ansa Biotechnologies, Inc.; Camena Bio; DNA Script; GenScript Biotech Corporation; Molecular Assemblies; Synbio Technologies; Telesis Bio Inc; Touchlight; and Twist Bioscience are a few leading companies operating in the North America enzymatic DNA synthesis market.